Foghorn Therapeutics Inc. (FHTX) shareholders
Close on Nov 16, 2026Market cap $106.30MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Noubar Afeyan Joint filing with Flagship Pioneering, LLC (10.00%), Flagship Ventures Fund V, L.P. (15.90%) and 3 more | 20,774,885 | 27.20% | 13D (active) amendment | Jan 9, 2026 |
| Bvf Inc/Il Joint filing with Bvf Partners L P/Il (14.30%), Lampert Mark N (14.30%) and 5 more | 8,507,000 | 14.30% | 13G (passive) amendment | Oct 1, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (11.60%) | 6,792,356 | 11.60% | 13G (passive) amendment | Mar 31, 2026 |
| Lampert Mark N Joint filing with Bvf Partners L P/Il (9.99%), Bvf Inc/Il (9.99%) and 3 more | 5,866,613 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Deerfield Partners, L.P. Joint filing with Deerfield Mgmt, L.P. (8.64%), Deerfield Management Company, L.P. (8.64%) and 1 more | 5,139,523 | 8.64% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FHTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Flagship Pioneering Inc. | 12,674,120 | 21.34% | $61.85M | – | 4.02% |
| Bvf Inc/Il | 5,842,000 | 9.84% | $28.51M | – | 0.73% |
| FMR LLC | 5,705,958 | 9.61% | $27.85M | −341,240 | 0.00% |
| Deerfield Management Company, L.P. (Series C) | 4,394,367 | 7.40% | $21.44M | – | 0.22% |
| BlackRock, Inc. | 2,626,832 | 4.42% | $12.82M | +261,966 | 0.00% |
| Raymond James Financial Inc | 2,489,978 | 4.19% | $12.15M | −112,404 | 0.00% |
| Euclidean Capital LLC | 1,573,761 | 2.65% | $7.68M | – | 1.75% |
| Vanguard Capital Management LLC | 1,494,611 | 2.52% | $7.29M | −478 | 0.00% |
| Geode Capital Management, LLC | 910,866 | 1.53% | $4.45M | +62,694 | 0.00% |
| Siren, L.L.C. | 720,720 | 1.21% | $3.52M | – | 0.07% |
| State Street Corp | 697,469 | 1.17% | $3.40M | +17,682 | 0.00% |
| Ameriprise Financial Inc | 558,685 | 0.94% | $2.73M | +109,709 | 0.00% |
| Renaissance Technologies LLC | 377,936 | 0.64% | $1.84M | −28,489 | 0.00% |
| Candriam S.C.A. | 313,765 | 0.53% | $1.53M | – | 0.01% |
| Northern Trust Corp | 309,775 | 0.52% | $1.51M | +33,900 | 0.00% |
| Jacobs Levy Equity Management, Inc | 305,434 | 0.51% | $1.49M | +1,677 | 0.01% |
| Vanguard Portfolio Management LLC | 304,432 | 0.51% | $1.49M | +48,501 | 0.00% |
| Birchview Capital, LP | 281,937 | 0.47% | $1.38M | +207 | 0.64% |
| Vanguard Fiduciary Trust Co | 264,422 | 0.45% | $1.29M | +23,836 | 0.00% |
| Qube Research & Technologies Ltd | 203,296 | 0.34% | $992.08K | +122,018 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 103 | 45M | 75.6% | 15 / 40 | 26 / 14 | 1M | 1M |
| Q1 2026 | 105 | 44M | 74.8% | 22 / 40 | 21 / 9 | 5M | 1M |
| Q4 2025 | 93 | 42M | 70.5% | 15 / 30 | 25 / 10 | 2M | 1M |
| Q3 2025 | 88 | 41M | 68.9% | 16 / 27 | 23 / 9 | 1M | 1M |
| Q2 2025 | 81 | 41M | 69.0% | 8 / 37 | 15 / 17 | 1M | 1M |
| Q1 2025 | 90 | 40M | 68.1% | 9 / 26 | 31 / 5 | 1M | 1M |
| Q4 2024 | 87 | 41M | 68.3% | 17 / 32 | 12 / 8 | 3M | 1M |
| Q3 2024 | 79 | 40M | 67.9% | 14 / 28 | 19 / 6 | 4M | 2M |
| Q2 2024 | 72 | 40M | 67.0% | 16 / 23 | 16 / 13 | 13M | 1M |
| Q1 2024 | 69 | 27M | 45.4% | 12 / 19 | 17 / 2 | 1M | 0M |
| Q4 2023 | 59 | 27M | 44.8% | 6 / 19 | 17 / 8 | 2M | 4M |
| Q3 2023 | 61 | 29M | 48.4% | 3 / 17 | 20 / 1 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
99 funds held FHTX in Q2 2026, 42% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of FHTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 1,836,447 | 3.09% | $7.86M | 0.01% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,027,071 | 1.73% | $5.01M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 896,556 | 1.51% | $4.38M | 0.01% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 501,007 | 0.84% | $2.14M | 0.01% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 428,310 | 0.72% | $2.09M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 396,371 | 0.67% | $1.80M | 0.01% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 351,578 | 0.59% | $1.50M | 0.03% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 342,513 | 0.58% | $1.67M | 0.01% | Jun 30, 2026 |
| Fidelity Series Growth Company Fund | 283,912 | 0.48% | $1.22M | 0.00% | May 31, 2026 |
| iShares Biotechnology ETF | 221,798 | 0.37% | $1.08M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 188,248 | 0.32% | $805.70K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 175,973 | 0.30% | $753.16K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 122,329 | 0.21% | $596.97K | 0.04% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 87,961 | 0.15% | $398.46K | 0.01% | Jul 31, 2026 |
| Ultra-Small Company Market Fund | 83,000 | 0.14% | $405.04K | 0.27% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Adrian Gottschalk | Chief Executive Officer, Director | 511,704 | 0.86% | Apr 13, 2026 |
| Ryan D. Maynard | Chief Financial Officer | – | – | Feb 24, 2026 |
| Anna Rivkin | Chief Business Officer | – | – | Feb 2, 2026 |
| Michael LaCascia | Chief Legal Officer | – | – | Feb 2, 2026 |
| Carlos Costa | Chief People Officer | 0 | – | Feb 2, 2026 |
| Alfonso Quintas Cardama | Chief Medical Officer | – | – | Feb 2, 2026 |
| Steven F. Bellon | Chief Scientific Officer | 151,957 | 0.26% | Feb 2, 2026 |
| Kristian Humer | Chief Financial Officer | – | – | Nov 17, 2025 |
| Thomas J. Lynch Jr. | Director | – | – | Jun 25, 2026 |
| Scott Biller | Director | – | – | Jun 25, 2026 |
| Michael Mendelsohn | Director | – | – | Jun 25, 2026 |
| Neil Gallagher | Director | – | – | Jun 25, 2026 |
| Stuart Duty | Director | – | – | Jun 25, 2026 |
| Simba Gill | Director | 34,061 | 0.06% | Jun 25, 2026 |
| Ian F. Smith | Director | 72,072 | 0.12% | Jun 25, 2026 |
| B. Lynne Parshall | Director | – | – | Jun 25, 2026 |
| Douglas G. Cole | Director | – | – | Jun 25, 2026 |
| Flagship Ventures Fund V, L.P. | Director, 10% owner | – | – | Jan 15, 2026 |
| Noubar Afeyan | Director, 10% owner | – | – | Jan 15, 2026 |
| Ventures Fund V. General Partner LLC Flagship | Director, 10% owner | – | – | Jan 15, 2026 |
| Flagship Pioneering, LLC | Director, 10% owner | – | – | Jan 15, 2026 |
| Ventures Opportunities Fund I. General Partner LLC Flagship | Director, 10% owner | 9,330,878 | 15.71% | Jan 15, 2026 |
| Flagship Pioneering Special Opportunities Fund II, L.P. | Director, 10% owner | – | – | Jan 15, 2026 |
| Flagship Ventures Opportunities Fund I, L.P. | Director, 10% owner | – | – | Jan 15, 2026 |
| Pioneering Special Opportunities Fund II General Partner LLC Flagship | Director, 10% owner | – | – | Jan 15, 2026 |
| Pioneering Fund VII General Partner LLC Flagship | Director, 10% owner | – | – | Jan 15, 2026 |
| Flagship Pioneering Fund VII, L.P. | Director, 10% owner | – | – | Jan 15, 2026 |
| Adam Koppel | Director | – | – | Dec 30, 2024 |
| Partners OS Ltd. BVF | 10% owner | – | – | Oct 5, 2026 |
| Value Fund L. P. Biotechnology | 10% owner | – | – | Oct 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Adrian Gottschalk Chief Executive Officer, Director | Apr 10, 2026 | Gift | −59,208 | – | – | 240,792 |
| Adrian Gottschalk Chief Executive Officer, Director | Apr 10, 2026 | Gift | +59,208 | – | – | 270,912 |
| Adrian Gottschalk Chief Executive Officer, Director | Apr 9, 2026 | Gift | +47,497 | – | – | 211,704 |
| Adrian Gottschalk Chief Executive Officer, Director | Apr 9, 2026 | Gift | −47,497 | – | – | 0 |
| Adrian Gottschalk Chief Executive Officer, Director | Apr 25, 2025 | Gift | +300,000 | – | – | 511,704 |
| Adrian Gottschalk Chief Executive Officer, Director | Apr 25, 2025 | Gift | −300,000 | – | – | 511,704 |
| Adrian Gottschalk Chief Executive Officer, Director | Apr 9, 2025 | Gift | +197,906 | – | – | 511,704 |
| Adrian Gottschalk Chief Executive Officer, Director | Apr 9, 2025 | Gift | −197,906 | – | – | 511,704 |
| Carlos Costa Chief People Officer | Sep 23, 2024 | Sale(10b5-1 plan) | −857 | $10.17 | $8.72K | 0 |
| Carlos Costa Chief People Officer | Sep 23, 2024 | Option exercise | +857 | $3.72 | $3.19K | 857 |
| Carlos Costa Chief People Officer | Sep 20, 2024 | Option exercise | +35,756 | $3.72 | $133.01K | 35,756 |
| Carlos Costa Chief People Officer | Sep 20, 2024 | Sale(10b5-1 plan) | −35,756 | $10.04 | $358.99K | 0 |
| Carlos Costa Chief People Officer | Sep 18, 2024 | Sale(10b5-1 plan) | −11,574 | $10.05 | $116.32K | 0 |
| Carlos Costa Chief People Officer | Sep 18, 2024 | Option exercise | +11,574 | $3.72 | $43.06K | 11,574 |
| Carlos Costa Chief People Officer | Sep 17, 2024 | Sale(10b5-1 plan) | −10,272 | $10.04 | $103.13K | 0 |
| Carlos Costa Chief People Officer | Sep 17, 2024 | Option exercise | +10,272 | $3.72 | $38.21K | 10,272 |
| Carlos Costa Chief People Officer | Sep 16, 2024 | Sale(10b5-1 plan) | −400 | $10.00 | $4.00K | 0 |
| Carlos Costa Chief People Officer | Sep 16, 2024 | Option exercise | +400 | $3.72 | $1.49K | 400 |
| Steven F. Bellon Chief Scientific Officer | Sep 9, 2024 | Sale(10b5-1 plan) | −20,000 | $9.50 | $190.00K | 101,957 |
| Fanny Cavalie Chief Strategy/Bus Ops Officer | Mar 11, 2024 | Sale | −11,000 | $6.56 | $72.16K | 75,992 |
| Adrian Gottschalk Chief Executive Officer, Director | Aug 17, 2023 | Gift | −63,000 | – | – | 0 |
| Adrian Gottschalk Chief Executive Officer, Director | Aug 17, 2023 | Gift | +63,000 | – | – | 511,704 |
| Samuel Agresta Chief Medical Officer | Aug 16, 2023 | Sale | −311,297 | $8.25 | $2.57M | 0 |
| Samuel Agresta Chief Medical Officer | Aug 16, 2023 | Option exercise | +311,297 | $3.72 | $1.16M | 311,297 |
| Adrian Gottschalk Chief Executive Officer, Director | May 26, 2023 | Gift | −300,000 | – | – | 448,704 |
| Adrian Gottschalk Chief Executive Officer, Director | May 26, 2023 | Gift | +300,000 | – | – | 448,704 |
| Adrian Gottschalk Chief Executive Officer, Director | Feb 17, 2023 | Gift | −4,371 | – | – | 63,000 |
| Adrian Gottschalk Chief Executive Officer, Director | Feb 17, 2023 | Gift | +4,371 | – | – | 448,704 |
| Adrian Gottschalk Chief Executive Officer, Director | Feb 17, 2023 | Other | −184,939 | – | – | 448,704 |
| Adrian Gottschalk Chief Executive Officer, Director | Feb 17, 2023 | Other | +184,939 | – | – | 448,704 |
| Adrian Gottschalk Chief Executive Officer, Director | Oct 25, 2022 | Other | −4,371 | – | – | 444,333 |
| Adrian Gottschalk Chief Executive Officer, Director | Oct 25, 2022 | Other | +4,371 | – | – | 67,371 |
| Adrian Gottschalk Chief Executive Officer, Director | Sep 16, 2022 | Option exercise | +40,000 | $0.54 | $21.60K | 186,479 |
| Simba Gill Director | Sep 13, 2022 | Gift | −47,939 | – | – | 34,061 |
| Simba Gill Director | Sep 12, 2022 | Option exercise | +82,000 | $0.73 | $59.86K | 82,000 |
| Steven F. Bellon Chief Scientific Officer | Aug 11, 2022 | Option exercise | +1,858 | $3.72 | $6.91K | 121,957 |
| Steven F. Bellon Chief Scientific Officer | May 25, 2022 | Option exercise | +3,717 | $3.72 | $13.83K | 120,099 |
| Steven F. Bellon Chief Scientific Officer | May 25, 2022 | Option exercise | +675 | $0.73 | $493 | 116,382 |
| Adrian Gottschalk Chief Executive Officer, Director | Feb 10, 2022 | Gift | +123,479 | – | – | 448,704 |
| Adrian Gottschalk Chief Executive Officer, Director | Feb 10, 2022 | Gift | −123,479 | – | – | 23,000 |
| Cigall Kadoch Director, 10% owner | Dec 14, 2021 | Gift | −333,333 | – | – | 295,000 |
| Carl Decicco Chief Scientific Officer | Dec 9, 2021 | Option exercise | +104,310 | $3.72 | $388.03K | 362,707 |
| Adrian Gottschalk Chief Executive Officer, Director | Aug 20, 2021 | Option exercise | +23,000 | $0.54 | $12.42K | 446,479 |
| Allan Reine Chief Financial Officer | Aug 9, 2021 | Option exercise | +26,892 | $3.72 | $100.04K | 53,784 |
| Carl Decicco Chief Scientific Officer | Oct 27, 2020 | Buy | +5,500 | $16.00 | $88.00K | 258,397 |
| Adrian Gottschalk See Remarks, Director | Oct 27, 2020 | Conversion | +25,225 | – | – | 25,225 |
| Ventures Opportunities Fund I. General Partner LLC Flagship 10% owner | Oct 27, 2020 | Buy | +50,000 | $16.00 | $800.00K | 9,330,878 |
| Ventures Opportunities Fund I. General Partner LLC Flagship 10% owner | Oct 27, 2020 | Conversion | +4,504,504 | – | – | 8,558,558 |
| Ventures Opportunities Fund I. General Partner LLC Flagship 10% owner | Oct 27, 2020 | Conversion | +4,054,054 | – | – | 4,054,054 |
| Ventures Opportunities Fund I. General Partner LLC Flagship 10% owner | Oct 27, 2020 | Conversion | +1,441,441 | – | – | 1,441,441 |
| Ventures Opportunities Fund I. General Partner LLC Flagship 10% owner | Oct 27, 2020 | Buy | +50,000 | $16.00 | $800.00K | 1,491,441 |
| Ventures Opportunities Fund I. General Partner LLC Flagship 10% owner | Oct 27, 2020 | Conversion | +722,320 | – | – | 9,280,878 |
| Ventures Opportunities Fund I. General Partner LLC Flagship 10% owner | Oct 27, 2020 | Conversion | +1,801,801 | – | – | 1,801,801 |
| Ventures Opportunities Fund I. General Partner LLC Flagship 10% owner | Oct 27, 2020 | Buy | +50,000 | $16.00 | $800.00K | 1,851,801 |
| Dhabi Investment Authority Abu – | Oct 27, 2020 | Buy | +150,000 | $16.00 | $2.40M | 1,231,081 |
| Dhabi Investment Authority Abu – | Oct 27, 2020 | Conversion | +1,081,081 | – | – | 1,081,081 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Foghorn Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 44,278 shares on Aug 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Carlos Costa Officer | Sep 16, 2024 | 98,648 | $958.86K | Sep 16, 2024 | Exercise of Stock Options |
| Steven F. Bellon Officer | Sep 9, 2024 | 20,000 | $150.60K | Sep 9, 2024 | Previously Exercised Options |
| Samuel Agresta Officer | Aug 16, 2023 | 311,297 | $2.57M | Aug 16, 2023 | Exercise of options under a registered plan |
See a number that looks wrong?